Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2023 / Apr / Discovering ERAP1 Inhibitors with MALDI-TOF MS
Mass Spectrometry

Discovering ERAP1 Inhibitors with MALDI-TOF MS

A new MALDI-TOF MS assay has set its sights on small molecule inhibitors of ERAP1 – a high profile target in drug discovery

By Georgia Hulme 04/20/2023 1 min read

Share

The dysregulation of endoplasmic reticulum aminopeptidase 1 (ERAP1) protein has been linked to cancer and both autoinflammatory and autoimmune diseases – making it a conspicuous therapeutic target for drug discovery. Existing high-throughput screening campaigns – such as fluorescence and chemiluminescence methods – are used to target specific proteins in a sea of interfering compounds. Unfortunately, these labed-based methods are susceptible to artifacts, and can often result in perturbed biology. 

A group of UK researchers decided to tackle these challenges by developing a high-throughput MALDI-TOF mass spectrometry (MS) assay to screen for small molecule inhibitors of ERAP1 (1). They based their assay on the existing in vitro RapidFire MS (RF MS) assay for greater reproducibility and robustness for the platform. The label-free nature of the assay was particularly valuable in the case of ERAP1, considering enzyme activity is mediated by the substrate’s structural features. 

The team discovered that the previous RF MS peptides – YTAFTIPSI substrate trimmed into the product TAFTIPSI – had low ionization efficiency and assay stability. Therefore, arginine residues were added into the peptide sequence to increase the limit and linearity of detection. The assay conditions were optimized and then validated with established ERAP1 inhibitors that targeted the active side of the enzyme.

Using their novel MALDI-TOF MS process, the researchers tested a set of 699 ERAP1 binders that had been previously identified through an affinity selection mass spectrometry screen. They first tested the compounds at a single concentration, before moving onto a dose-response format. The team compared the collection of compounds found using the new setup with the existing RF MS setup, noting that both platforms delivered similar results; however, the authors state that their MALDI-TOF MS setup saw additional benefits, such as shorter sample cycle times, lower reagent consumption, and a lower tight-binding limit – making it an effective candidate for ERAP1 screening.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. L. Müller et al., SLAS Discov, 28, 3 (2022). PMID: 36414185

About the Author(s)

Georgia Hulme

Georgia Hulme is Associate Editor at The Analytical Scientist

More Articles by Georgia Hulme

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.